---
title: "Petros Pharmaceuticals, Inc. (PTPI.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/PTPI.US.md"
symbol: "PTPI.US"
name: "Petros Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
---

# Petros Pharmaceuticals, Inc. (PTPI.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [etrospharma.com](https://etrospharma.com) |

## Company Profile

Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:16.000Z

**Overall: C (0.53)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 110 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1503.44% |  |
| Net Profit YoY | -183.59% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.11 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 355926.98 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 5.11M |  |


**Multi Score**: C

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -2085.03% | E |
| Profit Margin | -137.39% | E |
| Gross Margin | 0.00% | E |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1503.44% | A |
| Net Profit YoY | -183.59% | E |
| Total Assets YoY | -70.36% | E |
| Net Assets YoY | 8.05% | B |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -9.08% | D |
| OCF YoY | 1503.44% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.38 | C |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 45.09% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Petros Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-2085.03%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-137.39%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1503.44%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-183.59%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-70.36%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "8.05%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-9.08%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "1503.44%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.38",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "45.09%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Eli Lilly (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | Roche (US.RHHBY) | A | B | B | D | C | B |
| 04 | AstraZeneca (US.AZN) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.01 | 59/257 | - | - | - |
| PB | 0.11 | 3/257 | 0.28 | 0.19 | 0.11 |
| PS (TTM) | 0.07 | 4/257 | 0.25 | 0.19 | 0.07 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/PTPI.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/PTPI.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/PTPI.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.